EMEND 125mg + EMEND 80mg Price

Overview

Welcome to Dwaey, specifically on EMEND 125mg + EMEND 80mg page.
This medicine contains an important and useful components, as it consists of
Aprepitantis available in the market in concentration

Name

Aprepitant

Precaution

This medicine could make hormonal contraceptives, eg the pill, mini-pill or patch less effective at preventing pregnancy. If you are using hormonal contraceptives, you should use an extra back-up method of contraception, eg condoms, to prevent pregnancy, both during treatment with this medicine and for two months after the last dose. Lactation: It is not known whether this drug is excreted in milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Indication

Prevent nausea and vomiting caused by certain types of cancer medicines (chemotherapy), prevent nausea and vomiting after surgery.

Contra indication

Coadministration of astemizole, cisapride, pimozide, or terfenadine; hypersensitivity to any component of the product.

Side Effect

>10% (only seen in CINV) Headache,Asthenia/fatigue,Anorexia,Constipation,Diarrhea,Nausea,Alopecia,Hiccups 1-10% (selected) Dizziness,Insomnia,Bradycardia,Hypotension,Pharyngolargeal pain,Mucosal inflammation,Stomatitis,Dyspepsia,Anemia,Neutropenia,Hot flash,Pruritus,Dehydration,Fever

Pregnancy Category ID

2

Mode of Action

Aprepitant is an antiemetic which acts as a substance P/neurokinin 1 (NK1) receptor antagonist. It also enhances antiemetic activity of 5HT3 antagonists and corticosteroid.

Interaction

Concurrent use with CYP3A4 inhibitors (e.g. clarithromycin, troleandomycin, diltiazem, verapamil, itraconazole, ketoconazole, nefazodone, ritonavir, nelfinavir) may lead to increased plasma levels of Aprepitant; concurrent use with CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampicin, primidone, phenobarbital) may lead to reduced efficacy of Aprepitant. May decrease concentrations of CYP2C9 substrates e.g. phenytoin, tolbutamide, warfarin. May increase plasma levels of dexamethasone and methylprednisolone. May increase plasma levels of benzodiazepine (e.g. midazolam, diazepam, alprazolam). Serum concentrations of colchicine may increase with Aprepitant. May increase toxicity of chemotherapy drug metabolised by CYP3A4 e.g. docetaxel, etoposide, ifosfamide, imatinib, paclitaxel, vincristine, vinblastin. May increase levels of ergot derivatives resulting in ergotism. May reduce efficacy of oral contraceptives, use additional methods of contraception during treatment and for at least 1 mth following the last dose of Aprepitant. Potentially Fatal: May result in increased serum levels of astemizole, cisapride, pimozide and terfenadine which can lead to life-threatening torsade de pointes arrhythmias.

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration